Literature DB >> 8946204

Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers.

H Suzuki1, A Komiya, M Emi, H Kuramochi, T Shiraishi, R Yatani, J Shimazaki.   

Abstract

Human prostate cancers frequently show loss of heterozygosity (LOH) at loci on the long arm of chromosome 16 (16q). In this study, we analyzed prostate cancer specimens from 48 patients (Stage B, 20 cases; Stage C, 10 cases; cancer death, 18 cases) for allelic loss on 16q, using either restriction fragment length polymorphism (RFLP)- or polymerase chain reaction (PCR)-based methods. Allelic losses were observed in 20 (42%) of 48 cases, all of which were informative with at least one locus. Detailed deletion mapping identified three distinct commonly deleted regions on this chromosome arm: q22.1-q22.3, q23.2-q24.1, and q24.3-qter. On the basis of a published sex-averaged framework map, the estimated sizes of the commonly deleted regions were 4.7 (16q22.1-q22.3), 17.2 (16q23.2-q24.1) and 8.4 cM (16q24.3-qter). Allelic losses on 16q were observed more frequently in the cancer-death cases (11 of 18; 61%) than in early-stage tumor cases (9 of 30; 30%; P < 0.05). In 7 of 11 patients from whom DNA was available from metastatic cancers as well as from normal tissues and primary tumors, the primary cancer foci had no detectable abnormality of 16q, but the metastatic tumors showed LOH. These results suggest that inactivation of tumor suppressor genes on 16q plays an important role in the progression of prostate cancer. We also analyzed exons 5-8 of the E-cadherin gene, located at 16q22.1, in tumor DNA by means of PCR-single strand conformation polymorphism and direct sequencing, but we detected no somatic mutations in this candidate gene.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8946204     DOI: 10.1002/(SICI)1098-2264(199612)17:4<225::AID-GCC4>3.0.CO;2-5

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  15 in total

1.  A genome screen of multiplex sibships with prostate cancer.

Authors:  B K Suarez; J Lin; J K Burmester; K W Broman; J L Weber; T K Banerjee; K A Goddard; J S Witte; R C Elston; W J Catalona
Journal:  Am J Hum Genet       Date:  2000-03       Impact factor: 11.025

2.  Comprehensive genetic evaluation of common E-cadherin sequence variants and prostate cancer risk: strong confirmation of functional promoter SNP.

Authors:  Sara Lindström; Fredrik Wiklund; Björn-Anders Jonsson; Hans-Olov Adami; Katarina Bälter; Anthony J Brookes; Jianfeng Xu; S Lilly Zheng; William B Isaacs; Jan Adolfsson; Henrik Grönberg
Journal:  Hum Genet       Date:  2005-09-28       Impact factor: 4.132

3.  Genetics of prostate cancer.

Authors:  Kai Qi Zhang; Sherry A Salzman; D J Reding; Brian K Suarez; William J Catalona; James K Burmester
Journal:  Clin Med Res       Date:  2003-01

4.  Differentially expressed genes in hormone refractory prostate cancer: association with chromosomal regions involved with genetic aberrations.

Authors:  A P Stubbs; P D Abel; M Golding; G Bhangal; Q Wang; J Waxman; G W Stamp; E N Lalani
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

5.  N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion withStromal cells.

Authors:  N L Tran; R B Nagle; A E Cress; R L Heimark
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

6.  WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear.

Authors:  C Gourley; A J W Paige; K J Taylor; D Scott; N-J Francis; R Rush; C M Aldaz; J F Smyth; H Gabra
Journal:  Int J Oncol       Date:  2005-06       Impact factor: 5.650

7.  WWOX, the common chromosomal fragile site, FRA16D, cancer gene.

Authors:  J H Ludes-Meyers; A K Bednarek; N C Popescu; M Bedford; C M Aldaz
Journal:  Cytogenet Genome Res       Date:  2003       Impact factor: 1.636

8.  The human cadherin 11 is a pro-apoptotic tumor suppressor modulating cell stemness through Wnt/β-catenin signaling and silenced in common carcinomas.

Authors:  L Li; J Ying; H Li; Y Zhang; X Shu; Y Fan; J Tan; Y Cao; S W Tsao; G Srivastava; A T C Chan; Q Tao
Journal:  Oncogene       Date:  2011-12-05       Impact factor: 9.867

9.  Genetic and epigenetic changes in human prostate cancer.

Authors:  S Koochekpour
Journal:  Iran Red Crescent Med J       Date:  2011-02-01       Impact factor: 0.611

10.  Role of caveolin 1, E-cadherin, Enolase 2 and PKCalpha on resistance to methotrexate in human HT29 colon cancer cells.

Authors:  Elisabet Selga; Cristina Morales; Véronique Noé; Miguel A Peinado; Carlos J Ciudad
Journal:  BMC Med Genomics       Date:  2008-08-11       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.